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Highlights 
The role of Bcl-6 translocation in cerebral tumors is unclear. 
We have investigated Bcl-6 translocation in GBM, low-grade glioma, and meningioma. 
We have demonstrated that the Bcl-6 translocates in GBM. 
Translocation correlates with apoptosis inhibition, indicating a key role in GBM. 
Abstract 
Bcl-6 translocation is a genetic alteration that is commonly detected in Primary Central 
Nervous System Lymphoma. The role of this protein in cerebral tumors is unclear. In this 
study we investigated Bcl-6 translocation and its transcriptional and translational levels in 
formalin-fixed, paraffin-embedded cerebral tissue sections from glioblastoma (GBM), 
low-grade glioma (Astrocytoma grade II and III), and meningioma patients, and 
correlated them with apoptotic processes and p53 and caspase-3 expression. The 
results showed a frequency of 36.6% of Bcl-6 translocation in GBM patients and a 
decreased expression in low-grade glioma patients, correlated with the severity of the 
disease. Bcl-6 translocation induced an overexpression of both Bcl-6 protein and 
messenger in GBM, inhibiting apoptotic processes and caspases 3 expression. On the 
contrary, in low-grade gliomas and meningiomas Bcl-6 expression was reduced, 
resulting in an increase of apoptotic processes. Finally, p53 expression levels in brain 
tumors were comparable to Bcl-6 levels. Overall, these data demonstrate, for the first 
time, that the Bcl-6 gene translocates in GBM patients and that its translocation and 
expression are correlated with apoptosis inhibition, indicating a key role for this gene in 
the control of cellular proliferation. This study offers further insights into glioblastoma 
biology, and supports Bcl-6 as a new diagnostic marker to evaluate the disease severity. 
Keywords 
Brain tumors; Bcl-6; Glioma; Tumor progression 
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Introduction 
Glioblastoma (GBM) multiforme is one of the most common and aggressive primary 
brain tumors in adults. It is characterized by rapid proliferation, diffuse invasion, necrosis, 
high angiogenesis and resistance to treatment. Median survival ranges from 9 to 12 
months1 and2. Malignant gliomas are classified on the basis of their histopathological 
features and their degree of malignancy, as diffuse astrocytoma, grade II; anaplastic 
astrocytoma, grade III; and glioblastoma, grade IV3 . A distinction can also be made 
between secondary glioblastomas developing from pre-existing grade III gliomas, and de 
novo primary glioblastomas. 
In gliomas, many genetic alterations, such as TP53 mutations, epidermal growth factor 
receptor (EGFR) amplification, p16INK4a homozygous deletion, phosphatase and 
tensin4 homolog (PTEN) mutations, loss of heterozygosity (LOH) 10q, LOH 1p, and LOH 
19q and5, are recognizable, leading to the activation of oncogenes and inactivation of 
tumor suppressor genes. These genetic alterations interfere with critical cell cycle points, 
growth factor activation, apoptosis, cell motility and invasion pathways, and are 
responsible for phenotypic changes and neoplastic transformation6. Recently, somatic 
mutations of NADP+-dependent isocitrate dehydrogenase 1 (IDH1)7, now considered to 
be a highly selective molecular marker of GBMs8, have been identified. IDH1 mutations 
confer a new enzymatic function to this protein, leading to a potential indirect promotion 
of angiogenesis in glioma, and could also influence epigenetic regulation, suggesting an 
early role in glioma tumorigenesis9. Therefore, IDH1 mutations are more frequent in 
secondary GBMs and are often associated with TP53 mutations and LOH 19q, whereas 
GBMs without IDH1 mutations often show EGFR amplification8. 
B-cell lymphoma 6 (Bcl-6) is a proto-oncogene located on chromosome 3 band q27 
encoding a nuclear sequence-specific transcriptional repressor of 706 amino acids with a 
molecular weight of 78,846 Da. In normal conditions, Bcl-6 regulates germinal center 
(GC) formation and plays a central role in the regulation of B and T cell development, 
modulating the transcription of genes involved in cell proliferation, differentiation and 
apoptosis10,11and 12. By contrast, Bcl-6 is not expressed in other districts because its 
promoter is silent13. 
The breakpoints of Bcl-6 translocations are mainly clustered at the 5′ non-coding 
regulatory region, so Bcl-6 expression becomes deregulated by translocations in which 
heterologous promoters/enhancers replace normal Bcl-6 regulatory sequences 14 and 15. 
A translocation of Bcl-6 has been demonstrated in 20–40% of Primary Lymphomas of 
the Central Nervous System (PCNLS)16 and in a variety of lymphoid malignancies such 
as large B cell Lymphomas17,18 and 19. In lymphoma, several reports in literature have 
analyzed patients survival in terms of the incidence and a favorable20 and 21 or 
unfavorable prognosis17 of the Bcl-6 rearrangement. The biological significance of Bcl-6 
in GBM has not yet been elucidated and no evidence of genetic mutations involving the 
Bcl6 gene has yet been reported. 
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The purpose of this study was to analyze Bcl-6 gene expression, its protein and 
messenger content on biopsy specimens obtained from different groups of patients, 
affected by GBM, astrocytoma grade II/III, and low index of malignancy meningioma, 
using healthy human brain specimens as negative, and PCNLS as positive controls. 
FISH, immunohistochemistry with related densitometrical analysis, and Real Time PCR 
were performed. Moreover, because Bcl-6 is a transcriptional repressor of the genes 
involved in apoptosis, we correlated translocation of the Bcl6 gene with the degree of 
tumor aggressiveness and with the regulation of apoptotic processes, by Tunel assay, 
and with p53 and caspase-3 immunocytochemical expression, in all groups of samples. 
The results demonstrate, for the first time, a frequency of 36.6% of Bcl-6 translocation in 
GBM patients, and a progressive translocation decrease in other gliomas, paralleling the 
tumor aggressiveness. Moreover, both Bcl-6 protein and messenger are highly 
expressed in GBM and reduced in low malignancy astrocytoma grade II and 
meningioma. Bcl-6 overexpression is consistent with the degree of apoptosis reduction 
and with caspase-3 expression. On the contrary, p53 protein and messenger are 
strongly expressed in GBM as compared to astrocytoma II and meningioma, suggesting 
a role in inducing cellular damage. 
Overall, these results demonstrate that Bcl-6 gene translocation is a common feature of 
GBM as of PCNSL, and indicate Bcl-6 as a possible gene marker for glioma. They also 
suggest a putative role for Bcl-6 in the control of tumor cell proliferation and inhibition of 
apoptosis in glioblastoma. 
Materials and methods 
Tissue samples 
Primary human brain tumors were retrospectively selected from the archive of the 
Section of Pathology of the University of Torino, Medical School, and the Section of 
Pathology of the Department of Emergency Surgery and Organ Transplantation of the 
University of Bari, Medical School. The study was conducted in accordance with local 
ethics committee guidelines and the Helsinki Declaration. All primary tumors were 
obtained from patients who had undergone no prior treatment (radiotherapy or 
chemotherapy) and we showed in Table 1 the clinical, anatomical and molecular 
features of GBM patients. Tumor type and stage were determined according to the World 
Health Organization classification3, using conventional histology. Tumor specimens were 
obtained from 30 glioblastomas (grade IV), 19 astrocytomas grade III, 17 astrocytomas 
grade II, 16 PCNLS and 22 meningiomas and 5 healthy tissues, histologically confirmed, 
from patients who underwent neurosurgical treatments. Tissues were collected at the 
time of craniotomy, fixed in 10% buffered formalin for 24 h and paraffin-embedded. 
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Table 1.  
Clinical, anatomical and molecular features of glioblastoma patients. 
Case Age 
(years) 
Sex Ki-67 
(%) 
Tumor 
location 
Bcl6 
translocation (%)
Gene expression 
 
      Bcl6mIDH1w/m p53
1 67 M 60 Frontal lobe 40 + + + 
2 71 M 20 Frontal lobe − − − + 
3 58 F 30 Temporal lobe − − − ± 
4 52 M 40 Parieto-occipital lobe 32 + + + 
5 53 M 20 Thalamo − − − ± 
6 38 M 80 Temporal lobe 59 + + + 
7 64 F 20 Frontal lobe − − − + 
8 67 F 40 Frontal lobe 29 + + + 
9 57 M 35 Temporo-parietal lobe − − − + 
10 56 M 50 Parieto-occipital lobe 33 + + + 
11 45 F 25 Left temporal lobe − − − ± 
12 80 M 30 Left frontal lobe 20 + + + 
13 65 M 10 
Right 
parieto-
occipital lobe
− − − + 
14 81 M 40 Left frontal lobe 23 + + + 
15 42 M 30 
Right 
temporal 
lobe 
− − + + 
16 66 M 40 
Right 
parieto-
occipital lobe
− − + ± 
17 60 M 40 
Right 
temporal 
lobe 
− − + ± 
18 39 F 30 Left temporal lobe − − − + 
19 54 F 13 Left parieto-occipital lobe − − − + 
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Case Age 
(years) 
Sex Ki-67 
(%) 
Tumor 
location 
Bcl6 
translocation (%)
Gene expression 
 
      Bcl6mIDH1w/m p53
20 73 M 40 Left parietal lobe − − + + 
21 64 M 25 Left temporo-insular − − + + 
22 60 M 50 Right parietal lobe 37 + + + 
23 70 F 60 Left fronto-insular 43 + + + 
24 78 F 13 Left temporal lobe − − − ± 
25 43 M 30 
Right 
parieto-
occipital lobe
− − + ± 
26 61 M 20 Left frontal lobe − − − ± 
27 46 M 18 Left parietal lobe − − − + 
28 46 M 25 
Right 
temporo-
insular 
− − + + 
29 72 F 60 Occipital lobe 39 + + + 
30 43 M 50 Parietal lobe 42 + + + 
Ki-67 tumor proliferative index. 
Fish analysis 
Interphase FISH was performed on thin sections of formalin-fixed paraffin-embedded 
(FFPE) tumor samples. All cases were screened for Bcl6 translocation with a two-color 
break-apart probe (Cytocell, Cambridge, UK). In brief, 4-μm paraffin-embedded sections, 
mounted on coated slides, were deparaffinized and rehydrated. Slides were next 
incubated at 96 °C in Tris/EDTA acid buffer solution for 15 min, washed in sterile water 
and treated in 0.01 N HCl solution at 37 °C for 2 min. Enzymatic digestion was then 
induced by adding 200 μl 0.4% pepsin (Sigma–Aldrich, St. Louis, MO, USA) solution and 
incubating at 37 °C for 15 min. Thereafter, tissue samples were washed with sterile 
water, dehydrated in ethanol, and air dried. The Bcl-6 two-color break-apart probe was 
used for hybridization according to the manufacturer’s protocol. Probe and target were 
co-denatured at 75 °C for 5 min, followed by overnight hybridization at 37 °C on a 
StatSpinThermoBrite (Abbott Molecular, Abbott Park, Illinois, USA). Post-hybridization 
washing was carried out at 72 ± 1 °C in 0.4XSSC for 2 min and in 2XSSC/0.1% Tween 
at room temperature for 1 min. Then the slides were counterstained and mounted with 
DAPI-Antifade (Cytocell). 
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The interphase FISH analysis was performed using an Olympus BX51 fluorescence 
microscope (Olympus Italia, Rozzano, Italy) with 100X objective lenses and a triple 
band-pass filter for FITC, Texas Red and DAPI. Images were captured using a high-
resolution digital camera (DP70, Olympus Italia) transmitting image data to a PC 
equipped with appropriate software for images acquisition and analysis (AnalySIS, 
Olympus Italia). 
Hybridization signals were counted in 200 morphologically intact nuclei for each sample. 
Signals were considered colocalized when the distance between them was equal to or 
smaller than the size of one hybridization signal. Only co-localized green and red 
signals, often resulting in a yellow signal, were considered representative of intact Bcl-6 
loci. By contrast, a Bcl-6 translocation breakpoint is easily recognized by the presence of 
scattered single red and green signals. 
Immunofluorescence and fluorescence in situ hybridization analysis (FICTION) 
Fluorescence immunophenotyping and interphase cytogenetics (FICTION), a technique 
combining immunofluorescence and FISH, was carried out on 4-μm-thick paraffin 
sections of the glioblastoma samples. To identify chromosomal translocations in tumoral 
cells, FISH assay was performed and then the sections were stained with anti-IDH1 
antibody, a cytoplasmic glioblastoma tumoral cells marker which recognizes the 
isocitrate dehydrogenase 1 (IDH1) R132H point mutation. FISH was performed as 
described previously. After post-hybridization washing, immunostaining was performed. 
The tissues were treated with normal goat serum at room temperature for 30 min and 
incubated overnight with monoclonal mouse anti-human IDH1 R132H (Dianova, 
Hamburg, Germany) primary antibody at 22 °C, washed in PBS buffer and then 
incubated at room temperature for 2 h with Alexa Fluor 488 goat anti-mouse (Invitrogen, 
Carlsbad, CA, USA) antibody, used as secondary reagent. Afterwards, the slides were 
washed, counterstained with DAPI (Invitrogen), and mounted in Vectashield (Vector 
Laboratories, Burlingame, CA, USA). Images were captured using an Olympus BX51 
microscope fitted with an Olympus DP70 camera, equipped with filter sets for DAPI 
(nuclei counterstaining), FITC (cytoplasmic immunofluorescence signal and green 
nuclear FISH signal) and TRITC (red nuclear FISH signal). 
Terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling assay-
TUNEL test 
DNA cleavage was assessed by enzymatic end-labeling of DNA strand breaks using a In 
Situ Cell Death Detection Kit (Roche, Penzberg, Germany) according to the 
manufacturer’s protocol. Briefly, deparaffinized slides were washed in phosphate-
buffered saline (PBS) and permeabilized with 0.1% Triton X-100 and 0.1% sodium citrate 
for 2 min at 41 °C; after rinsing, slides were incubated with 50 ml of terminal 
deoxynucleotidyltransferase (TdT)-mediated dUTP nick end labeling (TUNEL) reaction 
mixture, containing TdT- and FITC-labeled dUTP, in a humidified atmosphere for 1 h at 
37 °C in the dark. Afterwards, slides were rinsed and mounted in antifade solution and 
images were captured as above with a FITC (TUNEL) filter. The percentages of 
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apoptotic human cells in tumoral sections were evaluated by morphometric analysis 
carried out on 10 cross reactions from each experimental group, 5 cases per group, 
using Image Analysis Software (Olympus Italia). 
Bcl-6, p53 and caspase 3 Immunohistochemistry 
Histological sections of 4 μm thickness, collected on poly- L-lysine-coated slides (Sigma 
Chemical, St Louis, MO, USA), were deparaffinized and stained in an automated 
immunostainer (DAKO Autostainer) with a dextran polymer-based system method 
(EnVision™ Flex+, DAKO) using 3′-3′ diaminobenzidine as chromogen. The sections 
were rehydrated in a xylene-graded alcohol scale and then rinsed for 10 min in 0.1 M 
PBS. For p53 and caspase 3 immunodetection, sections were pre-treated with sodium 
citrate pH 6.1 (Dako Corporation, Milan, Italy) solution for 30 min at 98 °C, for Bcl-6 with 
EDTA pH8 at the same time and temperature conditions, all in DAKO PT Link for antigen 
retrieval, and then incubated with monoclonal mouse anti-Bcl-6 (Dako), monoclonal 
mouse anti-p53 (Dako, Clone DO7), polyclonal rabbit anti-caspase 3 (Novus Biologicals), 
diluted 1:10, 1:50, 1:100, respectively. Thereafter, the sections were counterstained with 
Mayer hematoxylin and mounted in synthetic medium. Specific preimmune serum 
(Dako), replacing the primary antibodies, served as negative control. Morphometric 
analysis was performed on 10 sections from each experimental group, 5 cases per 
group, using Image Analysis Software (Olympus Italia). 
Real-Time PCR 
Total RNA was extracted from FFPE tissue blocks using the RecoverAll™ Total Nucleic 
Acid isolation kit (Ambion, Life Technologies, Inc., Austin, TX, USA) and then used to 
synthesize the first-strand c-DNA with the IScriptcDNA Synthesis kit (Bio-Rad 
Laboratories, Hercules, CA, USA), according to the manufacturer’s instructions. 
To detect Bcl-6 expression, cDNA was amplified with the iTaq SYBR Green supermix 
using a ROX kit (Bio-Rad Laboratories, Hercules, CA, USA) while for detection of p53 
and caspase 3 expression, cDNA was amplified with the SsoFast Probes Supermix (Bio-
Rad Laboratories). PCR amplification was performed using the Chromo4 Real-time PCR 
Detection System (Bio-Rad Laboratories). Samples were normalized to human RPLPO 
(large ribosomal protein PO). Table 2 and Table 3 show the sequences of primers 
(Sigma) used for Bcl-6 amplification and the taqman probes (Applied Biosystems, Life 
technologies) used for p53 and caspase 3 amplification, respectively. 
Table 2.  
Primer sequences for real-time PCR. 
BCL6/S 5′ CTGCATCAAGCCTCCTC 3′ 
BCL6/AS 5′ GTTCTCCACCACCTCACG 3′ 
RPLPO/S 5′ CCTTCCCACTTGCTGAAAAGG 3′
RPLPO/AS5′ ACAAAGGCAGATGGATCAGCC 3′
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Table 3.  
TaqMan gene expression assays for real-time PCR. 
RPLPOHs99999902_m1
CASP3 Hs00234385_m1
TP53 Hs01034253_m1
 
Protein extraction and Western Blotting 
15-μm thick sections were cut for total protein extraction, deparaffinized in xylene, 
rehydrated in graded ethanol and air-dried. The EXB lysis buffer (QProteome FFPE 
Tissue kit Qiagen, Hilden, Germany) was added to each samples, and the contents were 
pre-incubated at 100 C for 20 min before treatment at 80  C for 2 h. After incubation, the 
tissue lysates were centrifuged at 15,000 g for 20 min at 4°C. The supernatants were 
collected and stored at −80°C until use for protein assay and Western blot analysis. The 
protein concentration of the lysates was determined with the Bio-Rad DC Protein Assay 
(Bio-RadLaboratories, Hercules, CA, USA). For immunoblotting, 30 μg per lane of 
protein extract were solubilized in Laemmli buffer, boiled at 90°C for 5 min and resolved 
on a 10% polyacrylamide gel; thereafter, the proteins were electrotransferred to a 
nitrocellulose membrane (Biorad). Blots were blocked with PBS BB containing 5% non-
fat dry milk for 1h and incubated overnight at 4°C with the following primary antibodies: 
mouse anti-Bcl6 (Santa Cruz) diluted 1:200, mouse anti-p53 (Santa Cruz) diluted 1:100 
and mouse anti-RPLPO (Santa Cruz) diluted 1:1000. After the primary antibody 
treatment, the membranes were washed 4 times for 5min each at RT in PBS/0.1% 
Tween-20 before the addition of the secondary antibodies. PBS and 0.1% Tween-20- 
diluted secondary anti-mouse antibodies were IRDye labeled (800CW) (LI-COR 
Biosciences, Lincoln, NE, USA). For immunoblot analysis, the Li-corOdyssey infrared 
imaging system was used (LI-COR). The western blot images were analyzed by imaging 
densitometry using Quantity One Software (Bio-Rad Laboratories) and compared with 
RPLPO. The data were expressed as optical density/mm2. 
Statistical analysis 
Data are reported as means ± SEM. Newman-Keuls multiple comparison post test was 
used to compare all treatment groups after one-way ANOVA. The Graph Pad Prism 5.0 
statistical package (GraphPad Software, San Diego, CA, USA) was used for analyses 
and the limit for statistical significance was set at P < 0.05. 
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Results 
Bcl-6 translocation is correlated with the disease severity 
To investigate Bcl-6 translocation in brain tumors with different degrees of malignancy, 
(Table 1 and Table 4) interphase FISH analysis and FICTION technique, on thin sections 
of the FFPE tumor samples, were performed. The FICTION technique detected red and 
green separate fluorescent spots in the nuclei of glioblastoma IDH1 positive cells (white 
asterisk), indicating Bcl-6 translocation, (Fig. 1A and B), while close red and green 
fluorescent signals were present in IDHL-1-negative cells (Fig. 1C). Therefore, in 
glioblastomas positive IDH1 tumor cells are carriers of the Bcl-6 translocation. 
 
 
Table 4.  
Molecular features of different type of glioma tumors. 
 
Glioma 
histology 
Number 
of 
Patients 
mIDH1 
expression  
Bcl6 
translocation  
Bcl6 
expression
w/mp53 
expression
  Yes % Yes % Yes Yes 
Glioblastoma 
grade IV 30 18 60 11 36.6 11 30 
Astrocitoma 
grade III 19 2 11.7 3 15.8 3 19 
Astrocitoma 
grade II 17 3 15.7 2 11.8 2 17 
Meningioma 22 0 0 2 9 1 22 
 
 
 
Fig. 1. 
Bcl-6 translocation in glioblastoma patients by FICTION (A–C) and fluorescence in 
situ hybridization (FISH) (D) analysis on paraffin sections. (A and B) IDH1 green 
labeled tumoral cells (B, asterisk) show a red and green separate fluorescent spots 
in the nucleus (B, arrow) indicating a Bcl-6 translocation. (C) IDH1 negative cell 
shows a normal nucleus with close red and green fluorescent signals, indicating no 
Bcl-6 translocation. (D) Interphase FISH analysis shows a significant increase of Bcl-
6 mutations in glioblastoma patients (36.6% ± SE 3.059), a significant reduction in 
lymphomas (23.63% ± SE 0.25) and astrocytomas grade III (15.78 ± SE 0.92) and 
grade II (11.76 ± SE 1.02) and a return to basal conditions in meningiomas (9% ± SE 
1.17). *p < 0.05 vs other groups, $p < 0.05 vs meningiomas and control groups, 
#p < 0.05 vs control. Scale bar: A, 25 μm; B and C, 10 μm. (For interpretation of the 
references to color in this figure legend, the reader is referred to the web version of 
this article.) 
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Interphase FISH analysis showed a significant parallel increase of the Bcl-6 mutation 
with the degree of disease malignancy as compared to meningioma and healthy 
controls. 
In glioblastoma grade IV, rearrangement of Bcl-6 showed a frequency of 36.6% ± SE 
3.05%, versus a significant decrease, to 15.78% ± SE 0.92 and 11.76% ± SE 1.02%, in 
astrocytomas grade III and grade II, respectively. In meningioma sections the Bcl-6 
mutation was present only in 9% ± ES 1.17% and decreased to 0% in healthy controls 
(Fig. 1D). In the PCNSL sections, used as positive controls, the translocation frequency 
was 23.63% ± ES 0.25%. Table 1 and Table 4 showed number of patients positive for 
Bcl-6 translocation and mIDH1 expression in different type of glioma tumors. 
Bcl-6 gene expression is correlated with the severity of the disease 
To assess the Bcl-6 expression pattern, immunohistochemistry, western blotting analysis 
and Real Time-PCR assay were performed. As shown in Fig. 2(A–D), a strong 
immunocytochemical nuclear expression of Bcl-6 was seen in glioblastoma (A) 
specimens, while a reduction of Bcl-6 expression in astrocytoma grade III (B), PCNSL 
(C) and meningioma specimens (D) was detected. Morphometric analysis showed a 
significant difference in Bcl-6 expression between glioblastomas and PCNSL compared 
with astrocytoma grades II and III, meningiomas and controls patients (Fig. 2E). Western 
blotting analysis confirmed an overexpression of Bcl-6 protein in the tumor samples as 
compared to controls and significantly higher protein content levels in glioblastoma as 
compared with the other tumors (Fig. 3A and B). 
 
 
Fig. 2. 
Bcl-6 immunohistochemistry (A–D) and morphometric analysis (E). 
Glioblastoma sections show a strong Bcl-6 nuclear expression (A), which is 
reduced in grade III astrocytoma (B), lymphoma (C) and meningioma (D) 
sections. Morphometric analysis (E) reveals a significative increase of Bcl6 
protein in glioblastomas (25.75% ± SE 0.75) and lymphoma 
cases(16.77% ± SE 0.67), compared to astrocytomas grade III (9.17% ± SE 
0.36), astrocytomas grade II ((9.02% ± SE 0.24) and meningiomas 
(6.64% ± SE 0.75) cases. No Bcl6 protein is present in control (*p < 0.001 vs all 
groups, #p < 0.001 vs control). Scale bar A–D, 25 μm. 
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Fig. 3. 
Bcl-6 protein (A and B) and messenger (C) expression analysis Western blotting 
analysis (A and B) shows a high Bcl-6 expression in glioblastoma (1.12 ± SE 0.07) 
patients, and a significant reduction in lymphoma (0.70 ± SE 0.10), astrocytomas 
grade III (0.65 ± SE 0.05), astrocitomas grade II (0.72 ± SE 0.07), meningiomas 
(0.40 ± SE 0.10), and control brain (0.11 ± SE 0.01) (*p < 0.05 vs other groups, 
#p < 0.05 vs control). The RT–PCR analysis (C) shows a significant Bcl-6 
overexpression in glioblastomas (12.71 ± SE 2.17) as compared to lymphomas 
(2.89 ± SE 0.25), astrocytomas grade III (3.64 ± SE 0.51) and II (3.16 ± SE 0.42), 
meningiomas (1.31 ± SE 0.38) and to healthy brain (0.93 ± SE 0.07) (*p < 0.05 vs 
other groups). 
 
After Real Time-PCR (Fig. 3C), Bcl-6 mRNA was highly expressed in glioblastoma 
(12.71 ± SE 2.17) and significantly (P < 0.05) decreased in PCNSL (2.89 ± SE 0.25), 
astrocytoma grade III (3.65 ± SE 0.52) and grade II (3.16 ± SE 0.04) and in meningioma 
(1.32 ± SE 0.38) specimens. Bcl-6 mRNA was not detectable in the healthy brain 
tissues. 
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Bcl-6 protein promotes tumor cells proliferation through the inhibition of 
apoptosis and caspase-3 expression 
Bcl-6 is a transcriptional factor that induces cell proliferation and reduces apoptosis. We 
evaluated the degree of apoptosis in gliomas, PCNSL and meningiomas specimens, by 
means of the TUNEL assay and caspase-3 expression. 
As shown in Fig. 4(A–D), the TUNEL assay, which measures DNA strand breaks in 
individual cells, revealed no apoptosis in glioblastoma (A) and only few fluorescent 
apoptotic cells present in PCNSL (B) and in astrocytoma grade II (C) sections, whereas 
brighter green fluorescent cells were recognizable in meningiomas (D). Morphometric 
analysis demonstrated a lower percentage of apoptotic cells in glioblastomas 
(0.32% ± SE 0.09), PCNSL (0.7% ± SE 0.08) and astrocytomas grade III (0.99% ± SE 
0.46) as compared to astrocytomas grade II (1.69% ± SE 0.52) and meningiomas 
(2.53% ± SE 0.18) (Fig. 4E). The difference in apoptotic cells between aggressive and 
less aggressive tumors was significant (P < 0.05) and correlated with differences in Bcl-6 
expression. 
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Fig. 4. 
Apoptosis analysis. TUNEL assay shows no apoptosis in glioblastoma (A) and a 
progressive increase of fluorescent apoptotic cells in PCNSL (B), astrocytoma 
grade II (C) and in meningioma (D) sections. (E) Morphometric analysis reveals a 
lower percentage of apoptotic cells in glioblastomas (0.32% ± SE 0.09), 
lymphomas (0.7% ± SE 0.08) and grade III astrocytomas (0.99% ± SE 0.46) as 
compared to astrocytomas grade II (1.69% ± SE 0.52) and meningiomas. 
(2.53% ± SE 0.18) (*p < 0.05 vs astrocitomas and meningiomas groups, #p < 0.05 
vs meningiomas group). Scale bar, 16.6 μm. 
After caspase-3 immunohistochemical staining, in accordance with the TUNEL test 
results, a few labeled tumor cells were detected in glioblastoma, astrocytoma grade III 
and PCNSL sections (Fig. 5A–C) as compared with astrocytoma II and low meningioma 
(Fig. 5D and E). No caspase expression was detectable in healthy brain specimens (Fig. 
5F). Morphometric analysis confirmed a significant difference in caspase-3 expression 
between meningioma and astrocytoma grade II as compared with glioblastoma, PCNSL 
and astrocytoma grade III (Fig. 5G). 
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Fig. 5. 
Caspase-3 immunohistochemistry (A–G) and gene expression analysis (H). 
Glioblastoma (A), astrocytoma III (B) and PCNSL (C) sections show a lower 
expression of caspase-3, which is significantly increased in astrocytoma grade II (D) 
and meningioma (E) sections No caspase-3 expression is revealed in healthy brain 
controls (F). (*p < 0.05 vs astrocytoma and meningioma groups). Morphometric 
analysis (G) reveals a lower caspase-3 expression in glioblastomas (0.98% ± SE 
0.03), lymphomas (0.49% ± SE 0.22) and astrocytomas grade III (2% ± SE 0.02) as 
compared to astrocytomas grade II (5.49% ± SE 1.26) and meningiomas 
(11.10% ± SE 1.23). RT–PCR analysis (H) shows a strong expression of caspase-3 in 
meningiomas (1.32 ± SE 0.32) and astrocytomas grade II (0.91 ± SE 0.25), and a 
significant decrease in astrocytomas grade III (0.15 ± SE 0.15) and PCNSL (0.26 ± ES 
0.08). No caspase-3 mRNA is present in glioblastoma (*p < 0.05 vs astrocytomas II 
and meningiomas groups). Scale bar, A–F 25 μm. 
 
After Real Time-PCR (Fig. 5H), caspase-3 mRNA was most strongly expressed in 
meningiomas (1.32 ± SE 0.32) and astrocytomas grade II (0.91 ± SE 0.26), and 
significantly (P < 0.05) decreased in astrocytomas grade III (0.15 ± SE 0.15) and in 
PCNSL (0.26 ± SE 0.08). No caspase-3 mRNA was detected in glioblastoma sections. 
 
Bcl-6 and p53 protein expression are correlated 
We also studied p53 expression in the brain tumor specimens, since Bcl-6 is a gene 
promoter involved in p53 protein regulation. After immunohistochemistry and Real Time-
PCR we found a high p53 protein expression and mRNA content in glioblastoma and 
astrocytoma grade III (Fig. 6A, B, E and F) and a significantly decreased expression in 
astrocytoma grade II (Fig. 6C, E and F) and meningioma (Fig. 6D–F) specimens. p53 
protein and mRNA were not detectable in the in healthy brain tissues (Fig. 6E and F). 
Western blotting analysis confirmed a p53 protein overexpression in the tumor samples 
as compared to controls, and significantly higher protein content levels in glioblastoma 
as compared with the other tumors (Fig. 7A and B). Table 1 and Table 4 showed number 
of patients positive for wt/m p53 expression in different type of glioma tumors. 
 
 
Fig. 6. 
p53 immunohistochemistry (A–E), and gene expression analysis (F). 
Glioblastoma (A) and astrocytoma grade III (B) sections show numerous p53-
labeled tumor cells, which are significantly decreased in grade II astrocytoma 
(C) and meningioma (D) sections. Morphometric analysis (E) confirms 
significative reduction of p53 protein from glioblastomas (4.93% ± SE 0.56) and 
astrocytomas grade III (3.30% ± SE 0.10) cases to astrocytomas grade II 
(1.30 ± SE 0.10) meningiomas (1.26% ± SE 0.24) and control brain 
(0.46% ± SE 0.08). (*p < 0.05 glioblastoma and astrocytoma grade III vs all 
groups). RT–PCR analysis (F) shows that p53 is significantly overexpressed in 
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glioblastomas (12.0 ± SE 1.84) and astrocytomas grade III (10.85 ± SE 0.7) 
as compared to astrocytomas grade II (1.83 ± SE 0.07), meningiomas 
(1.37 ± SE 0.16) and healthy brain (0.15 ± SE 0.07) (*p < 0.05 
glioblastoma vs astrocytoma grades II, meningioma, and control brain; 
#p < 0.05 astrocytoma grade III vs astrocytoma grade II, meningiomas, 
and control brain). Scale bar, A–D 25 μm. 
 
 
 
 
Fig. 7. 
p53 protein expression analysis (A and B). Western 
blotting analysis shows a high p53 expression in 
glioblastoma 0.43 ± SE 0.01) patients, and a 
significant reduction in astrocytomas grade III 
(0.31 ± SE 0.02), astrocytomas grade II (0.17 ± SE 
0.03) meningiomas (0.15 ± SE 0.01), and control 
brain(0.01 ± SE 0.0) (*p < 0.05 vs other groups). 
 
Discussion 
In this study, we have demonstrated the presence of Bcl6 translocation in glioma brain 
tumors and confirmed the incidence in PCNSL. In addition, we have shown a correlation 
between the frequency of Bcl6 translocation and tumor aggressiveness, suggesting a 
potential role for this gene in tumorigenesis. The Bcl6 gene is fully expressed only in 
germinal centers, where it induces proliferation and differentiation of B and CD4+ T 
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cells22 and 23 and contributes to the regulation of immune responses24. The two common 
genomic alterations, translocations and somatic mutations, affecting this gene, may lead 
to a deregulation of B-cell maturation and contribute to lymphomagenesis25 and26. This 
gene is normally silent or expressed at low levels in a wide variety of tissues but its 
translocation leads to substitution of the Bcl6 promoter by heterologous sequences 
derived from the different translocation partners, resulting in constitutive expression of 
the Bcl6 gene10 and27. We found that Bcl6 translocations are recurrent in the nuclei of 
glioblastoma IDH1 cells confirming that this mutation is related to tumorigenesis. Somatic 
mutations of IDH1 are frequently observed in grade II and III gliomas and secondary 
glioblastomas28 and29. The IDH1 gene encodes isocitrate dehydrogenase 1 which 
catalyzes the oxidative carboxylation of isocitrate to α-ketoglutarate, resulting in the 
production of NADPH in the Krebs cycle30. IDH1 mutations, resulting in amino acid 
substitutions at a single arginine residue, inhibit wild-type IDH1 activity31. The cytosolic 
expression of mutant IDH1 reduces the formation of α-ketoglutarate and increases the 
levels of the hypoxia-inducible factor (HIF-1α) subunit, leading to vascular endothelial 
growth factor (VEGF) expression, which induces tumor angiogenesis32 and33. 
Furthermore, we have demonstrated, for the first time in brain tumors, a significant 
increase of Bcl6 expression at both transcriptional and translational levels, and its 
correlation with the gene rearrangement and the degree of tumor malignancy. RT–PCR, 
Western Blotting and immunohistochemistry analysis shows that Bcl6 is significantly 
overexpressed in grade IV glioma as compared to PCNSL, to grade III and II 
astrocytoma, to meningioma and to healthy brain. Numerous targets of Bcl6 suppressive 
effects have been identified, including genes implicated in B cell activation and 
differentiation, inflammation, cell cycle, DNA repair, chromatin formation, transcriptional 
regulation, and protein stability, in both normal and malignant B cells34 and 35. 
Furthermore, Bcl6 can repress several oncogenes and interact with various co-
repressors in order to repress genes involved in a variety of different biologic 
pathways35. Certainly, deregulation of Bcl6 results in perturbation of the proteins that 
control apoptosis; some works have shown that a high expression of Bcl6 induces 
apoptosis36 and37, while others found that Bcl-6 protects the cells from apoptosis34, 38, 39 
and 40. The precise role of Bcl-6 in enhancing or inhibiting apoptosis is still unclear. 
In this study we have shown that Bcl-6 plays a role in the repression of apoptosis in 
human cancer cells, and that at least one mechanism through which this occurs is by 
inactivating caspase 3, a key protein in the cascade of events leading to apoptosis. We 
have demonstrated that a reduced apoptosis is correlated with rearrangement of the 
gene and with the degree of tumor malignancy. In fact, in the cancer cells of 
glioblastoma, apoptosis is almost absent, while it rises in the tumor cells of PCNSL, 
grade III and II astrocytomas and is significantly increased in meningiomas. In support of 
these findings, Real Time and immunohistochemical studies in human benign 
meningiomas and in gliomas show that the expression of Bcl-6 and of caspase 3 is 
inversely correlated in these tumors, Bcl-6 expression being high but caspase-3 low or 
not detectable. The Bcl-6 transcript and the related protein are more strongly expressed 
in glioblastoma than in other glioma tumors and PCNSL, although Bcl-6 expression is 
indicative of the latter disease. 
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Several studies have reported that the p53 tumor suppressor gene is directly targeted by 
Bcl-641. Bcl-6 suppresses p53 gene expression and modulates DNA damage-induced 
apoptotic responses in germinal-center B cells facilitating expansion41. p53 is activated in 
response to a variety of cellular and genotoxic stress conditions, leading to the induction 
of growth arrest, apoptosis, DNA repair, senescence, and differentiation42. However, 
several studies obtained contradictory results regarding the relationship between p53 
and Bcl-6 expression. Although Bcl-6 can directly repress p53 in the germinal center, we 
have found that the p53 gene is expressed in gliomas as a translated transcript, and that 
it is also more strongly expressed in glioblastomas in correlation with Bcl-6 expression. 
This observation suggests that repression of Bcl-6 target genes, such as p53, is partly 
dependent on the cellular context 43. The fact that both mRNA and protein are increased 
in the presence of Bcl6 is consistent with previous reports showing that several types of 
cellular stress can cause a similar effect 44and 45. Shvarts et al. 46 reported that Bcl6 
might be able to bypass induced senescence in primary mouse embryonic fibroblasts 
and in a mixed population of human B-cells, and that Bcl6-mediated induction of cyclin 
D1 could explain this effect. We hypothesize that, unlike in germinal centers, in 
glioblastoma tissues the cells are unable to evade the p53 response to Bcl6 including 
growth arrest and senescence. Ranuncolo et al. 47 reported that when B-cells transit 
through the germinal center they acquire the ability to evade p53 checkpoint activity, 
which is not entirely dependent on the repressor activity of Bcl6, but can be mediated by 
some still unknown factor. Similarly to Bcl-6 expression, higher p53 levels were recorded 
in immunoproliferative small intestinal disease cases with a poor outcome, whereas a 
lower level was found in other cases in remission at follow-up 48. Moreover, a mutant 
form of p53 is overexpressed by many malignant tumors including lymphomas and 
glioblastomas 2 and 49. 
Taken together, these data indicate that even if p53 is overexpressed, it is likely not 
functional, being mutated or because the apoptosis inhibitor action of BCL6 is 
predominant in tumors such as glioblastoma. Furthermore, Margalit et al. 50 identified 
Bcl-6 as a new target gene of p53 and showed that the Bcl-6 gene contains a p53 
response element (RE) residing within the chromosomal translocations, point mutations, 
and deletions region in B-cell non Hodgkin lymphoma. But in contrast to these authors’ 
hypotheses, we postulate that this novel p53-bcl6 auto-regulatory loop could allow p53 
suppression of Bcl-6, then inducing apoptosis and repairing cell damage in physiological 
conditions. We also assume that p53 binding to the RE is abrogated in glioblastoma 
cases due to the Bcl-6 translocation located in the RE, resulting in a deregulation of Bcl-
6 expression. Thus, the translocation of Bcl6 not only allows the gene to be transcribed 
from a new coding sequence but also to evade the suppression induced by p53 in 
human gliomas is present as a protein and as a messenger but does not exert its 
function, while Bcl6 inhibits apoptosis and so allows proliferation of tumor cells. In this 
scenario, in germinal centers p53 is activated upon induction of cell proliferation induced 
by Bcl-6 and in response to the breaks formed in the genomic DNA due to Ig gene 
somatic hypermutation and class switch recombination 51 and52. Thereby, p53 limits the 
oncogenic potential of these breaks and down-regulates Bcl-6, causing a return to 
baseline levels and defining a tightly controlled time window for the completion of B-cell 
maturation. In this time window, during successive differentiation cycles Bcl-6 may 
temporarily inhibit p53 from promoting apoptosis and preventing cell proliferation. Thus, 
  22
while in germinal centers p53 and Bcl-6 are antagonists with different expression levels 
depending on the cell cycle phase, in glioma tumors the expression of Bcl-6 and p53 is 
correlated, and increased in relation to Bcl-6 translocation and the tumor 
aggressiveness. 
Although previous studies have reported that translocations may indicate a favorable 
prognosis20,21and 53, an unfavorable prognosis17and 54, or no effect 14and 21, in our study, 
Bcl-6 translocation combined with a high expression of Bcl-6 and p53 genes appears to 
be a poor prognostic indicator and a potential new gene marker for gliomas. 
Finally, we suggest that, in these conditions of elevated p53 expression, gene therapy 
experiments could be conducted to induce apoptosis and reduce the tumor 
aggressiveness, through a re-establishment of the regulatory loop of Bcl-6 and its basal 
conditions. 
Future research directions will aim to identify potential partner genes for Bcl6 
translocation as well as functional studies in glioma cells carrying or not Bcl-6 
translocation to validate the presence of the p53-Bcl-6 auto-regulatory loop involved in 
gliomagenesis processes. 
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